Karyopharm Therapeutics (KPTI) Operating Leases (2019 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Operating Leases came in at $5.7 million in Q4 2025, down 14.44% YoY from $6.7 million in Q4 2024, and down 4.41% on a QoQ basis from $6.0 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Operating Leases (2019 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Operating Leases data on file, last reported at $5.7 million in Q4 2025.
- Quarterly Operating Leases fell 14.44% year-over-year to $5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.7 million (down 14.44% YoY) and the FY2025 annual result came in at $5.7 million, down 14.44% from the prior year.
- Operating Leases fell to $5.7 million in Q4 2025, from $6.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $10.7 million in Q1 2021 to a low of $955000.0 in Q2 2024.
- A 5-year average of $6.2 million and a median of $6.3 million in 2025 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2024 — Operating Leases slumped 78.78% — and 2025, when it surged 554.55%.
- Tracing KPTI's Operating Leases over 5 years: stood at $9.0 million in 2021, then sank by 32.02% to $6.1 million in 2022, then sank by 54.26% to $2.8 million in 2023, then surged by 140.66% to $6.7 million in 2024, then dropped by 14.44% to $5.7 million in 2025.
- The last three Operating Leases figures came in at $5.7 million (Q4 2025), $6.0 million (Q3 2025), and $6.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.18 Mn |
| Dec 31, 2025 | 5.74 Mn |
| Sep 30, 2025 | 6.01 Mn |
| Jun 30, 2025 | 6.25 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Jun 30, 2024 | 955,000.00 |
| Mar 31, 2024 | 1.88 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Sep 30, 2023 | 3.67 Mn |
| Jun 30, 2023 | 4.50 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 6.10 Mn |
| Sep 30, 2022 | 6.86 Mn |
| Jun 30, 2022 | 7.58 Mn |
| Mar 31, 2022 | 8.29 Mn |
| Dec 31, 2021 | 8.97 Mn |
| Sep 30, 2021 | 9.63 Mn |
| Jun 30, 2021 | 10.20 Mn |
| Mar 31, 2021 | 10.75 Mn |